Senti Bio 10-Q Confirms Going Concern, Details Celadon Merger and Dilution
SNTI sits 26% above its 52-week low of $0.333 on elevated volume (2.4× avg).
Summary
Senti Bio's Q2 2026 10-Q confirms going concern with cash only into Q4 2026, details the Celadon merger's dilution (up to 77.5% ownership), and discloses $4.0M in additional convertible notes.
Key Events · Earnings and Guidance · SNTI
-
Going Concern Confirmed
Cash of $6.5M as of June 30, 2026 is not sufficient for one year; company may not maintain operations as early as Q4 2026.
-
Additional Convertible Notes Issued
On August 14, 2026, Senti Holdings issued $4.0M in additional notes (net proceeds $3.9M); $2.0M more is obligated under the Merger Agreement.
-
Dilution Quantified
If all notes are exchanged, Celadon could own 62.3% (with $6M additional notes) or 77.5% (with full $30M tranche) of common stock.
-
CVR Milestones Detailed
Stockholders receive CVRs worth up to $60M: $10M on BLA filing, $20M on FDA approval, $30M on sales >$200M.
Analysis · SNTI · Life Sciences
Senti Bio's Q2 2026 report confirms the company may not maintain operations as early as Q4 2026 with only $6.5M in cash. The filing also quantifies the Celadon-led merger's dilution: if all notes are exchanged, Celadon could own up to 77.5% of the company. The $4.0M additional notes issued on August 14, 2026 provide short-term runway but come with a 200% maturity repayment obligation. The going concern warning and potential delisting risk make this a critical update for shareholders.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.8% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $0.33 to $2.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.